We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

HAMAMATSU PHOTONICS

Hamamatsu Photonics develops, manufactures and markets optical sensors, photodiodes, photo ICs, image sensors and oth... read more Featured Products: More products

Download Mobile App




Infrared Signature for Mobile Phone Detects Malaria

By LabMedica International staff writers
Posted on 13 Dec 2022

Optical microscopy, rapid diagnostic tests (RDTs) and molecular tests are the three main diagnostic techniques currently available for malaria diagnosis. More...

Microscopy is the traditional way of detecting malaria parasites in stained thick or thin peripheral blood films using Giemsa, Wrights or Fields stains.

RDTs detect malaria antigens in blood by targeting falciparum-specific protein such as histidine-rich protein II (HRP-II) or lactate dehydrogenase (LDH). RDTs are simple, relatively cheap and can be used in remote areas without specialized equipment or need for electricity. However, RDTs can only reliably detect 50-100 parasites/ µL. Molecular tests such as polymerase chain reaction (PCR) are currently the most accurate and the most sensitive techniques for detecting malaria in low or sub-microscopic samples, for mixed infections and for differentiating Plasmodium species.

An international team of Tropical Medicine Specialists aided by those at The University of Queensland (Brisbane, Australia) hypothesized that the presence of malaria parasites in red blood cells produce unique infrared signatures that could potentially be used for malaria detection. They used a handheld near infrared spectrometer reflective (NIRS) model to non-invasively collect spectral signatures from the right and left ears, arms and fingers of malaria positive and negative individuals living in a malaria endemic area in Brazil where both P. falciparum and P. vivax are prevalent at a 30%/70% ratio. A total of 60 patients were scanned and a total of 360 spectra were collected. The infection status and Plasmodium species type were confirmed by microscopy and standard PCR.

The scientists uses the NIRvascan NIRS model G1 (Allied Scientific Pro, Gatineau, QC . Canada). The model used is a diffuse reflectance spectrometer with wavelength ranging from 900-1700nm, a 5000:1 signal to noise ratio and an optical resolution of 10nm pixel resolution. It has an inGaAs detector (Hamamatsu Photonics, Herrsching Germany), and it weighs 136g and measures 82.2 × 63× 40 mm, it is rechargeable and can be operated by either a computer or a smart-phone via Bluetooth.

The investigators reported that results from PCR confirmed 27/60 (45%) people scanned were positive with malaria while the rest were malaria negative. Of the malaria positive individuals, 75% (N=20) and 25% (N=7), were infected with P. vivax and P. falciparum, respectively. Results from microscopy indicated that out of the 27 infected patients, 7.4% (two subjects) had extremely high parasitaemia, 18.5% (five subjects) had moderate parasitaemia, 44.4% (12 subjects) had low parasitaemia and 29.6% (eight subjects) had very low parasitaemia.

Spectra collected from the ear produced the most accurate prediction of infection in the independent subjects with an accuracy of 92% (N=24), sensitivity of 100% (N=11) and specificity of 85% (N=13). Comparatively, the accuracy, sensitivity and specificity of the spectra collected from the finger was 70% (N=24), 72 (N=11) and 69% (N=13), respectively whereas spectra of the arm resulted into a predictive accuracy of 72% (N=24), sensitivity of 59% (N=11) and specificity of 85% (N=13).

The authors concluded that their proof-of-concept study provides insights on the potential application of NIRS and machine learning techniques for rapid, non-invasive and large-scale surveillance of malaria and potentially other human pathogens. The study was published on December 7, 2022 in the journal PNAS Nexus.

Related Links:
The University of Queensland 
Allied Scientific Pro
Hamamatsu Photonics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.